-
Product Insights
Liposarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Liposarcoma - Drugs In Development, 2023’, provides an overview of the Liposarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liposarcoma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of...
-
Product Insights
Mesenchymal Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Mesenchymal Tumor - Drugs In Development, 2023’, provides an overview of the Mesenchymal Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mesenchymal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Non-Rhabdomyosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-Rhabdomyosarcoma - Drugs In Development, 2023’, provides an overview of the Non-Rhabdomyosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Drugs In Development, 2023’, provides an overview of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in High-Grade Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in High-Grade Glioma Drug Details: Cemiplimab (Libtayo) is an anti-neoplastic agent. It is formulated...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PPMX-T002 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PPMX-T002 in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PPMX-T002 in Fallopian Tube Cancer Drug Details: PPMX-T002 (FF-21101) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – interferon gamma-1b in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - interferon gamma-1b in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interferon gamma-1b in Ovarian Cancer Drug Details: Human interferon gamma-1b...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – interferon gamma-1b in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - interferon gamma-1b in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interferon gamma-1b in Non-Small Cell Lung Cancer Drug...